We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pentraxin-3 level at admission is a strong predictor of short-term mortality in a community-based hospital setting.
- Authors
Bastrup‐Birk, S.; Munthe‐Fog, L.; Skjoedt, M.‐O.; Ma, Y. J.; Nielsen, H.; Køber, L.; Nielsen, O. W.; Iversen, K.; Garred, P.
- Abstract
Background The pattern recognition molecule pentraxin-3 ( PTX3) is a novel potential marker of prognosis, as elevated levels are associated with both disease severity and mortality in patients with a wide range of conditions. However, the usefulness of PTX3 as a prognostic biomarker in a general hospital setting is unknown. Patients and methods The study cohort consisted of 1326 unselected, consecutive patients (age >40 years) admitted to a community hospital in Copenhagen, Denmark. Patients were followed until death or for a median of 11.5 years after admission. The main outcome measure was all-cause mortality. Serum samples collected from patients at admission and from 192 healthy control subjects were quantified for PTX3 level by enzyme-linked immunosorbent assay. Results PTX3 was elevated in patients (median 3.7 ng mL−1, range 0.5-209.8) compared with healthy nonhospitalized subjects (median 3.5 ng mL−1, range 0.0-8.3; P = 0.0003). Elevated PTX3 levels, defined as above the 95th percentile of the concentration in healthy subjects, were associated with increased overall mortality during the study ( P < 0.0001). This increase in mortality was greatest in the short term, with an unadjusted hazard ratio (HR) of 6.4 [95% confidence interval (CI) 3.8-11.0] at 28 days after admission, compared to 1.7 (95% CI 1.4-2.0) at the end of follow-up. These results were still significant after adjustment for age, gender and glomerular filtration rate: adjusted HR of 5.0 (95% CI 2.9-8.8) and 1.4 (95% CI 1.2-1.8), respectively. Conclusion These results suggest that PTX3 could be a widely applicable marker of short-term mortality in hospitalized patients and may be useful in the initial risk stratification.
- Subjects
PENTRAXINS; HOSPITAL mortality; BIOMARKERS; ENZYME-linked immunosorbent assay; ACUTE phase proteins
- Publication
Journal of Internal Medicine, 2015, Vol 277, Issue 5, p562
- ISSN
0954-6820
- Publication type
Article
- DOI
10.1111/joim.12294